Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00316602
Status:
COMPLETED
Last Update Posted:
2019-01-09
First Post:
2006-04-20
Brief Title:
A Phase II Study on Immunogenicity and Safety of MVA-BN IMVAMUNE Smallpox Vaccine in Subjects With Atopic Dermatitis
Sponsor:
Bavarian Nordic
Organization:
Bavarian Nordic
Study Overview
Official Title:
A Multicenter Open-label Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN IMVAMUNE Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HHSN266200400072C | OTHER_GRANT | NIAID | None |